Like antibodies in the 1990s, drugs targeting RNA are approaching a major breakthrough. The main challenges have been managed, the industry and investors are excited, and the RNA field could potentially be the next billion-dollar adventure for biotech firms.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.